NuVasive, Inc. to Present at the Thomas Weisel Partners Annual Healthcare Conference
Published: Sep 04, 2009
SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- NuVasive, Inc. , a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Chief Financial Officer and Executive Vice President, is scheduled to present at the Thomas Weisel Healthcare Conference at The Four Seasons Hotel in Boston, Massachusetts, on Wednesday, September 9, 2009, at 9:45 a.m. ET.
NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.
CONTACT: Kevin C. O'Boyle, EVP & Chief Financial Officer, +1-858-909-1998,
firstname.lastname@example.org, or Investors: Patrick F. Williams, Vice
President, Finance & Investor Relations, +1-858-638-5511,
email@example.com, both of NuVasive, Inc.; or Media: Jason
Rando, The Ruth Group, +1-646-536-7025, firstname.lastname@example.org
Web site: http://www.nuvasive.com/